Mesa Laboratories, Inc. (NASDAQ: MLAB) is a Healthcare company (Medical - Specialties) with a market capitalization of $757M. The Maz Rating grades it against the other companies in its sector.
Mesa Laboratories, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $134.60, Mesa Laboratories, Inc. trades at 113.5x trailing earnings, 3.0x sales and 3.9x book value, with an EV/EBITDA of 18.7. Over the last twelve months it generated about $253M of revenue and $7M of net income. It runs a gross margin of 66.6%, an operating margin of 10.4% and a net margin of 2.7%. It shows return on equity of 3.5%, return on invested capital of 3.6% and a free cash flow yield of 6.5%. On the balance sheet: a debt-to-equity ratio of 0.42 and a current ratio of 1.90. Over the past 52 weeks the share price ranged from $69.51 to $144.35, with a beta of 1.08.
Mesa Laboratories, Inc. pays a dividend yielding 0.48%, with 53% of earnings paid out. Its Maz Dividend Score is 2.70 out of 5, ranked against the other dividend payers in its sector (Safety 4.23, Growth 1.23, Yield 2.37, Consistency 2.59).
8 Wall Street analyst ratings cover the stock: 3 Buy and 5 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment’s products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Mesa Laboratories, Inc. (MLAB) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.88% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.08% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.88% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.08% / 33% · Receivables / Mkt Cap (36m) 5.44% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.88% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.08% / 33.33% · Receivables / Mkt Cap (24m) 5.44% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 28.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.45% / 33.33% · Receivables / Avg Assets (4Q) 9.36% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 15.8% / 33.33% · (Cash+ST Inv) / Total Assets 5.47% / 33.33% · (Cash+Recv) / Total Assets 15.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Mesa Laboratories, Inc. (MLAB) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Mesa Laboratories, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Mesa Laboratories, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.